Who Paid My Doc
Swaiman Singh
Advanced Heart Failure and Transplant Cardiology Rochester, MN Medical Doctor
NPI 1386026565 CMS profile 1357141
200 1St St Sw, Rochester, MN 55905
General payments
$9,412
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Swaiman Singh of Rochester, MN is reported in the CMS Open Payments database as having received $9,412 across 178 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 56th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,844 | 43 | |
| 2024 | General | $1,678 | 19 | |
| 2023 | General | $758 | 10 | |
| 2022 | General | $319 | 7 | |
| 2021 | General | $53 | 3 | |
| 2020 | General | $1,898 | 35 | |
| 2019 | General | $1,861 | 61 |
Beside peers
- Swaiman Singh
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Swaiman Singh were reported at $2,844. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Swaiman Singh | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,861 | $863 | $224–$4,562 | $163 |
| 2020 | $1,898 | $452 | $122–$3,992 | $114 |
| 2021 | $53 | $550 | $159–$3,571 | $132 |
| 2022 | $319 | $729 | $221–$4,357 | $149 |
| 2023 | $758 | $1,002 | $309–$5,827 | $160 |
| 2024 | $1,678 | $931 | $273–$5,204 | $164 |
| 2025 | $2,844 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
178 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Advanced Heart Failure and Transplant Cardiology in Minnesota
Mosi Bennett
Advanced Heart Failure and Transplant Cardiology · Minneapolis, MN
Barry Borlaug
Advanced Heart Failure and Transplant Cardiology · Rochester, MN
Robert Frantz
Advanced Heart Failure and Transplant Cardiology · Rochester, MN
Terrie-Ann Benjamin
Advanced Heart Failure and Transplant Cardiology · Saint Paul, MN
Valmiki Maharaj
Advanced Heart Failure and Transplant Cardiology · Minneapolis, MN
Omar Abouezzeddine
Advanced Heart Failure and Transplant Cardiology · Rochester, MN
Related records
Advanced Heart Failure and Transplant Cardiology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.